Nls Pharmaceutic - NLSPW STOCK NEWS

NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announced its participation at the American Society of Clinical Psychopharmacology (ASCP) annual meeting from May 30 to June 2, 2023, in Miami, Florida. The company's Chief Scientific Officer, Dr. Eric Konofal, will present new preclinical data on four pipeline compounds targeting chronic fatigue and memory issues associated with CNS disorders. The presentations include:

• NLS-4: Effects on chronic severe fatigue - June 1, 2023
• NLS-8: Effects on memory in Alzheimer's model - June 1, 2023
• NLS-11: Effects on memory - May 31, 2023
• NLS-12: Effects on memory - May 31, 2023

The company emphasizes its commitment to developing innovative therapies for patients with rare CNS disorders.

NLS Pharmaceutics Ltd. announced results from its six-month Open Label Extension (OLE) study for Quilience® (Mazindol ER) in treating narcolepsy. Of the 60 patients completing the Phase 2 trial, 87% continued into the OLE, showing increased effectiveness in managing excessive daytime sleepiness and cataplexy episodes. Patients previously on placebo also achieved similar results after switching to Mazindol ER. Overall, the safety and tolerability profile remained consistent, with no serious adverse events reported. The Phase 3 program is set to begin mid-2023 after an FDA meeting in late April.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) announced that CEO Alex Zwyer will present at the 35th Annual Roth Conference on March 13, 2023, at 10:00 AM PT (1:00 PM ET) in Dana Point, CA.

The conference will include small group meetings, analyst-led fireside chats, and company presentations from around 400 private and public companies across various sectors.

Live audio webcasts and replays will be available in the investor relations section of the Company's website.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has completed the six-month Open Label Extension (OLE) study for Mazindol ER, a treatment for narcolepsy. The study included patients who previously participated in the POLARIS Phase 2 study. Notably, 87% of the patients opted to continue Mazindol ER treatment rather than switch therapies. The OLE aims to assess long-term safety, tolerability, and efficacy for Excessive Daytime Sleepiness (EDS) and cataplexy, showing promising results in interim data. Full results are expected in Q1 2023 and will be presented at a scientific meeting.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announced on January 25, 2023, that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies to maintain a minimum stockholders' equity of $2,500,000. This follows a notification letter from the Nasdaq Hearings Panel confirming the company's adherence to the rule. NLS was first notified of its non-compliance on April 1, 2022, but through an appeal process, it received approval to continue its Nasdaq listing. The Panel's recent confirmation resolves all outstanding compliance issues.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced new in vitro study results showing that mazindol ER exhibits significant agonist activity at the Orexin-2 receptor, which is crucial for treating narcolepsy. The Phase 2 trials for Quilience (mazindol ER) met primary endpoints with high statistical significance, indicating its potential as a dual mechanism treatment for narcolepsy. The drug offers a unique profile as it targets orexin loss rather than merely treating symptoms. The Phase 3 program is set to begin mid-2023, with additional studies planned to further confirm efficacy and safety.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) announced an upcoming R&D Day on January 31, 2023, at 10:00 am EST to discuss its strategic pipeline for 2023, focusing on innovative therapies for rare CNS disorders. Key programs include NLS-13 for idiopathic hypersomnia, NLS-3 targeting ADHD, NLS-4 for chronic fatigue syndrome, NLS-8 addressing Alzheimer's amnesia, NLS-11 for Kleine-Levin Syndrome, and NLS-12 for Lewy body dementia. Promising preclinical results and orphan drug designations highlight the company's commitment to meeting unmet medical needs in CNS disorders.